Cat. No：GM-88013MAB
Product：Anti-IL23A hIgG1 Reference Antibody (Risbio)
Cat. No：GM-88013MAB
Product：Anti-IL23A hIgG1 Reference Antibody (Risbio)
GM-88013MAB-1mg / 1 mg
GM-88013MAB-5mg / 5 mg
GM-88013MAB-25mg / 5 mg * 5 vials
GM-88013MAB-50mg / 50 mg
GM-88013MAB-100mg / 50 mg * 2 vials
Expression System | CHO |
Aggregation | < 5% as determined by SEC-HPLC |
Purity | > 95% as determined by SDS-PAGE |
Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
Sterility | 0.2 μm Filtered |
Target | IL23A |
Clone | risankizumab |
Alternative Names | IL-23, IL-23A, IL23P19, P19, SGRF |
Source/Isotype | Human IgG1(LALA REEM), Kappa |
Application | Bioactivity-ELISA |
Description | IL-23A encodes the p19 subunit of Interleukin-23, a cytokine that plays an important role in the immune response and is secreted by dendritic cells, macrophages and other Antigen-presenting cell. Risankizumab (Skyrizi) is a humanized monoclonal antibody that works by targeting the p19 subunit of Interleukin-23(Il-23) . RISANKIZUMAB specifically binds to the p19 subunit of Il-23 and blocks the interaction between IL-23 and its receptor, thereby inhibiting Th17 cell differentiation and the release of proinflammatory factors such as Il-17 and Il-22. Risankizumab alleviates pathological damage by inhibiting the IL-23/Th17 inflammatory axis, reducing inflammatory cell infiltration and cytokine storm in tissues such as the skin, intestine, and so on. |
Formulation | phosphate-buffered solution, pH 7.2-7.4. |
Cat. No：GM-88013MAB
Product：Anti-IL23A hIgG1 Reference Antibody (Risbio)
GM-88013MAB-1mg / 1 mg
GM-88013MAB-5mg / 5 mg
GM-88013MAB-25mg / 5 mg * 5 vials
GM-88013MAB-50mg / 50 mg
GM-88013MAB-100mg / 50 mg * 2 vials
Expression System | CHO |
Aggregation | < 5% as determined by SEC-HPLC |
Purity | > 95% as determined by SDS-PAGE |
Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
Sterility | 0.2 μm Filtered |
Target | IL23A |
Clone | risankizumab |
Alternative Names | IL-23, IL-23A, IL23P19, P19, SGRF |
Source/Isotype | Human IgG1(LALA REEM), Kappa |
Application | Bioactivity-ELISA |
Description | IL-23A encodes the p19 subunit of Interleukin-23, a cytokine that plays an important role in the immune response and is secreted by dendritic cells, macrophages and other Antigen-presenting cell. Risankizumab (Skyrizi) is a humanized monoclonal antibody that works by targeting the p19 subunit of Interleukin-23(Il-23) . RISANKIZUMAB specifically binds to the p19 subunit of Il-23 and blocks the interaction between IL-23 and its receptor, thereby inhibiting Th17 cell differentiation and the release of proinflammatory factors such as Il-17 and Il-22. Risankizumab alleviates pathological damage by inhibiting the IL-23/Th17 inflammatory axis, reducing inflammatory cell infiltration and cytokine storm in tissues such as the skin, intestine, and so on. |
Formulation | phosphate-buffered solution, pH 7.2-7.4. |
